<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109706</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/10/03-ZE</org_study_id>
    <nct_id>NCT01109706</nct_id>
  </id_info>
  <brief_title>Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.</brief_title>
  <acronym>PC-SCA-9</acronym>
  <official_title>Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PCSK9 (Proprotein convertase subtilisin kexin type 9) plays a key role in LDL-cholesterol&#xD;
      (LDLC) metabolism by inhibiting LDL receptor (LDLR) at post-transcriptional level. PCSK9 loss&#xD;
      of function mutations are associated to decreased LDLC levels and a cardiovascular&#xD;
      protection. In this context, the development of pharmacological inhibitors of PCSK9, in&#xD;
      association with statins treatment, represents a major therapeutic issue for LDLC modulation.&#xD;
      It was previously shown that PCSK9 plasmatic concentration correlated with plasmatic LDLC, TG&#xD;
      and glucose concentrations. However, no data are available on predictive value of PCSK9&#xD;
      plasmatic level concerning coronary disease severity.&#xD;
&#xD;
      The main objective of this study is to determine whether plasmatic PCSK9 concentration is&#xD;
      linked to coronary damage severity in patients with acute coronary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2011</start_date>
  <completion_date type="Actual">July 16, 2015</completion_date>
  <primary_completion_date type="Actual">September 24, 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Syntax score (for evaluate coronary damages) and plasmatic concentration of PCSK9</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
    <description>Assessing the correlation between plasma concentration of PCSK9 and coronary damage severity in patients with acute coronary syndrome. Coronary lesions will be measured using the SYNTAX score (J0: admission day), and PCSK9 concentration will be evaluated using blood analysis (J0 (admission), J1, J2, J3 &amp; J4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between PCSK9 and morbidity/mortality</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
    <description>Assessing the correlation between plasma PCSK9 (J1, J2, J3, J4) concentration and one-year morbidity/mortality of patients with acute coronary syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>association between PCSK9 and metabolic/inflammatory factors</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
    <description>Identification of metabolic and inflammatory factors (glycemia, insulinemia, HbA1C, CRPusâ€¦) associated to plasma PCSK9 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kinetic of PCSK9 for statin-treated patients</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
    <description>Measurement of PCSK9 kinetic variation during ACS acute phase in patients treated with artovastatin 80 mg/day (J1, J2, J3, and J4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kinetic of PCSK9 after intensive care</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
    <description>Determination of PCSK9 kinetic variation at 1 and 6 months after intensive care, during their normal follow-up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">175</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>patient treated by statines</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patient without normolipidemic treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biological parameters dosage</intervention_name>
    <description>200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).&#xD;
After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).&#xD;
Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up.</description>
    <arm_group_label>patient treated by statines</arm_group_label>
    <arm_group_label>patient without normolipidemic treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of both sexes, 18 years old minimum, with an acute coronary syndrome, treated or&#xD;
        not with statins, admitted to cardiological intensive care unit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  more than 18 years old&#xD;
&#xD;
          -  Acute coronary syndrome (ST+ or ST-)&#xD;
&#xD;
          -  2 groups of patients: with statin, and without statin treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient who had cancer during the last 5 years or with cancer in progress&#xD;
&#xD;
          -  Patient with severe infection in progress&#xD;
&#xD;
          -  Hepatic failure (TP&lt;50%)&#xD;
&#xD;
          -  Severe kidney failure&#xD;
&#xD;
          -  Patient unable to give his consent to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Cariou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nantes University hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>PCSK9</keyword>
  <keyword>cardiovascular safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

